POLITICO @politico
The FDA’s approval of a controversial new Alzheimer’s drug this week has hardened opposition to acting commissioner Janet Woodcock, who remains President Joe Biden’s apparent favorite to be the agency’s permanent leader https://t.co/M8dJzHlNC1 — PolitiTweet.org